One Dose HPV Vaccine As Effective As Three-Dose Schedules Against Cervical Cancers
Wednesday, June 10, 2015 - 05:06
in Health & Medicine
A single dose of the bivalent human papillomavirus (HPV) vaccine (Cervarix) offers a similar level of protection against the HPV-16/18 infections - which cause about 70% of cervical cancers - as current two- and three-dose schedules, according to data from two large phase 3 trials. Worldwide, cervical cancer is the fourth most common cancer in women. The bivalent vaccine targets HPV types 16 and 18 that are responsible for about 70% of cervical cancers. The HPV-16/18 vaccine was initially approved to be given in three doses over 6 months, but many countries are moving to a two-dose schedule in adolescents. read more